Dr McGregor on the Data for Abemaciclib in Advanced ccRCC

Bradley McGregor, MD, director, Clinical Research, Lank Center of Genitourinary Oncology, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses findings from a phase 1b study (NCT04627064) evaluating abemaciclib (Verzenio) in patients with clear cell renal cell carcinoma (ccRCC).

None of the patients who received abemaciclib (n = 11) achieved a response, with 8 patients experiencing disease progression and 1 achieving stable disease. However, the safety profile of the agent was tolerable. Although the study was negative, the findings offer insights into the interpretation of ongoing trials of CDK4/6 inhibitors in combination with other agents for patients with ccRCC, Bradley says.